share_log

Cybin | SUPPL: Voluntary supplemental material filed pursuant to Section 11(a) of the Securities Act of 1933 by foreign issuers

SEC announcement ·  Apr 18 08:51
Summary by Moomoo AI
Cybin Inc. (Cybin), a clinical-stage biopharmaceutical company, has announced the completion of a private placement offering of 348,837,210 common shares at a price of US$0.43 per share, resulting in gross proceeds of approximately US$150 million. The placement was led by Bloom Burton Securities Inc., with participation from Haywood Securities Inc. The offering, completed on March 19, 2024, is part of Cybin's efforts to raise capital for its ongoing research and development programs, including its proprietary deuterated psilocybin analog CYB003 for major depressive disorder and CYB004, a deuterated version of DMT for generalized anxiety disorder. The company's financial position is strengthened by this capital raise, which will support its strategic initiatives and growth plans. Cybin's shares are listed on the NEO Exchange...Show More
Cybin Inc. (Cybin), a clinical-stage biopharmaceutical company, has announced the completion of a private placement offering of 348,837,210 common shares at a price of US$0.43 per share, resulting in gross proceeds of approximately US$150 million. The placement was led by Bloom Burton Securities Inc., with participation from Haywood Securities Inc. The offering, completed on March 19, 2024, is part of Cybin's efforts to raise capital for its ongoing research and development programs, including its proprietary deuterated psilocybin analog CYB003 for major depressive disorder and CYB004, a deuterated version of DMT for generalized anxiety disorder. The company's financial position is strengthened by this capital raise, which will support its strategic initiatives and growth plans. Cybin's shares are listed on the NEO Exchange under the symbol 'CYBN' and on the NYSE American LLC exchange. The company's focus on developing psychedelic-based therapeutics aims to address unmet needs in mental health conditions, with a commitment to rigorous scientific research and clinical trials. Cybin's operations comply with all applicable laws and regulations in the jurisdictions where it operates, and it does not engage in any activities related to the illegal selling, production, or distribution of substances.

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more